Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,301 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $38.39, for a total transaction of $49,945.39. Following the sale, the insider directly owned 77,694 shares of the company’s stock, valued at approximately $2,982,672.66. The trade was a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of CSTL stock opened at $32.03 on Friday. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The firm has a market capitalization of $978.52 million, a P/E ratio of -48.53 and a beta of 0.98. The company’s fifty day moving average price is $23.77 and its two-hundred day moving average price is $26.20.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. On average, research analysts anticipate that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Castle Biosciences News Summary

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and indicates potential upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle Biosciences’ latest earnings exceeded expectations. Revenue was $99.86 million versus the $86.23 million consensus estimate, while the company reported a per-share loss of $0.07 compared with the expected $0.41 loss. Although CSTL remains unprofitable, the narrower-than-expected loss and stronger revenue support an improving operating outlook.
• Neutral Sentiment: Institutional investors own approximately 92.6% of CSTL’s shares. Recent purchases or stake increases by firms including AQR Capital Management, Amundi, Legal & General and Mirae Asset may provide shareholder support, but these ownership changes are not necessarily immediate trading catalysts.
• Negative Sentiment: Several company insiders disclosed sizable stock sales. Derek J. Maetzold sold more than 39,000 shares for approximately $1.21 million in August 4–5 transactions, while COO Kristen Oelschlager sold 8,586 shares worth about $256,000. Tobin W. Juvenal separately sold 1,301 shares for roughly $50,000. The sales reduced the insiders’ positions and could pressure sentiment, particularly following CSTL’s recent advance. However, all of the reported transactions were executed under pre-arranged Rule 10b5-1 trading plans, making them a less definitive bearish signal. Castle Biosciences insider sales

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC bought a new position in Castle Biosciences during the second quarter worth $26,000. Federated Hermes Inc. bought a new stake in Castle Biosciences during the fourth quarter valued at $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Castle Biosciences during the fourth quarter worth $35,000. Jones Financial Companies Lllp lifted its position in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Castle Biosciences by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock worth $55,000 after buying an additional 297 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CSTL. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective on the stock. KeyCorp set a $35.00 target price on Castle Biosciences in a research report on Friday, May 29th. BTIG Research raised their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Canaccord Genuity Group decreased their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Finally, Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.